Best Stock on the Market

Call Options on NVAX on 8/5/2016

Trading Channel with 50-day MA on NVAXNovavax, Inc. (NVAX) is a clinical-stage vaccine company.

The company focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants.

The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.

Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial.

The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants.

Shares are heading higher in an upward trading channel (shown in blue). The formation is supported by the stock's 50-day moving average (shown in green.) Higher share prices are expected for this stock. The firm report its quarterly results on August 8th.

 We will be trading September 16th call options.

 

52-Week Trading Range: $4.08 - $15.01

Entry Point: $7.51

 

Trade

  • Buy 1 September $7.00 Call at $1.95
  • For a net debit of $1.95

Profit/Loss Analysis

  • Breakeven at $8.95
  • Maximum profit is unbounded
  • Maximum loss is ($195.00) at strike of $7.00

Closing Summary

  • Sold 1 September $7.00 Call at $1.30

Position closed on 9/14/2016 at price of $1.30 with a -33.33% loss in 40 days.

Updates

9/14/2016 9:54:41 AM

We are closing NVAX September 16th Call Options at $1.30

Back to Portfolio